News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Immunic CEO says Q2 results "couldn't be better"

Immunic Inc

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business during Q2 "couldn't have been better", highlighting what he calls "scientifically a very good quarter and uneventful on the more general financial side." He goes on to give more detail about the progress achieved with Immunic's prospective multiple sclerosis (MS) and celiac disease treatments during the quarter, noting the preclinical data for its most advanced molecule IMU-838 that was published in the Journal of Medicinal Chemistry and positive results From Phase 1b Clinical Trial of IMU-856 in celiac disease. Looking to the future, Dr. Vitt expects more trial data to be released in the fall of this year, and reiterates that the company is fully funded into Q4 of 2024. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

August 07, 2023 09:50 AM Eastern Daylight Time

Video
Article thumbnail News Release

Ilika CEO says Cirtec deal an "absolutely fantastic validation"

Ilika PLC

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy speaks to Thomas Warner from Proactive after announcing the signing of a 10-year agreement with US complex medical device company Cirtec Medical to provide Ilika's Stereax solid-state batteries. The deal establishes an exclusive relationship with Cirtech for the use of Stereax batteries in medical devices and features an initial period of profit sharing, later transitioning into a royalty on net sales, ensuring mutual benefit. He refers to the deal as an "absolutely fantastic verification and validation" of Ilika's business model. Purdy suggests that despite Stereax's potential suitability for use in sectors such as the Internet of Things, he's always been clear that the initial commercial focus for Ilika during Stereax's early life will be on medical devices. He also mentions what he calls exciting progress with the other side of the business, the much larger Goliath Electric Vehicle (EV) batteries, and signals more positive developments in the future. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 07, 2023 08:21 AM Eastern Daylight Time

Video
Article thumbnail News Release

C4X Discovery focused and funded after £15.95mln strategic divestment

C4X Discovery Holdings PLC

C4X Discovery Holdings PLC (AIM:C4XD) chief business officer Bhavna Hunjan and chief scientific officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced what it calls the strategic divestment of its Orexin-1 receptor antagonist programme to Indivior PLC (LSE:INDV) for £15.95mln. In the divestment, C4X Discovery has sold the proprietary rights to its Orexin-1 antagonist programme for substance use disorders, including the lead candidate INDV-2000, to Indivior. This allows the company to crystallise the value of the programme, providing non-diluted funding for its future platform strategy. Bhavna Hunjan explains that the deal offers an opportunity to realise the value of the programme sooner, aligning with their focus on immuno-inflammatory diseases and providing valuable non-dilutive funding for the company. Nick Ray adds that the divestment is in line with their strategy to move forward as an immuno-inflammatory focused company. He reveals more about the company's pipeline, saying that good progress is being made toward the clinic with their lead programme and have several early-stage projects that will be further developed and disclosed to the public when ready. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 07, 2023 08:01 AM Eastern Daylight Time

Video
Article thumbnail News Release

MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC

MIRA Pharmaceuticals

MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive's Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol 'MIRA'. Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage. This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School revealed that this compound not only alleviates anxiety and chronic pain but also enhances cognition by 100% in animal studies. MIRA's synthetic THC is intended for medicinal use and is undergoing FDA approval. The pharmaceutical-grade version aims to provide a clean, safe, and effective option for patients, allowing them access to cannabis-based relief without the impurities and toxicity associated with plant-based marijuana. Moreover, MIRA's product stands out by being unscheduled, making it available to federal employees and veterans. The company's mission is to address unmet needs, such as anxiety and cognitive impairment in early-stage dementia patients, with minimal side effects. MIRA Pharmaceuticals raised $8.9 million in the IPO, which will be primarily directed towards accelerating toxicology and clinical research to bring the revolutionary drug to market. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 03, 2023 02:40 PM Eastern Daylight Time

Video
Article thumbnail News Release

Stupid Cancer to host CancerCon™ Live in Atlanta, Georgia in August 2023

Stupid Cancer, Inc.

New York, NY - Stupid Cancer, a 501(c)3 nonprofit leader in the adolescent and young adult (AYA) cancer community, announces it will be hosting their annual CancerCon Live at the Omni Hotel at the CNN Center in Atlanta, GA, this summer on August 17–20. CancerCon Live aims to connect AYA cancer patients, survivors, advocates, and health professionals for a weekend filled with inspiring discussions and networking opportunities. “We are excited to bring this event to the southeast to such a young and vibrant city!” says Alison Silberman, CEO of Stupid Cancer. The 2023 agenda is carefully curated to provide the AYA community with valuable resources and many opportunities to connect with your AYA community. Some of this year’s sessions and presenters include… A Community for Caregivers Speaker: Leeann Terwilliger, LCSW, Stupid Cancer I’m Fine: Men, Cancer, and "Cowboy Culture” Speaker: Trevor Maxwell, Man Up to Cancer LOLing through Cancer: Turning your Story into Comedy Speaker: Julia Johns, Comedian Do I Need a Lawyer? Legal Implications of AYA Cancer Speaker: Nicole Jolicoeur, Esq, Triage Cancer Peds to AYA & Long-Term Survivorship Speakers: Sanyukta Janardan, MD, Children's Healthcare of Atlanta/Emory University; Montana Harstad, RN, Emory Healthcare; & James Ludemann, MSN, RN, Children's Healthcare of Atlanta “We're thrilled to have several amazing local experts from Atlanta's renowned medical institutions as session presenters, as well as other survivors and professionals from across the country." says Chelsea Donahue, Director of Programs. For over a decade, Stupid Cancer has brought together hundreds of patients, survivors, caregivers, advocates, and health professionals at the largest gathering of the AYA community - CancerCon. Now gathering both online and off, every CancerCon event is an immersive experience, led by transformative connection and education.The majority of conference attendees are AYA (age 15-39) cancer patients and survivors, but caregivers and health professionals of all ages are also welcome. Beginning in 2022 CancerCon is hosted in a different US city as we seek to make the event always be within reach of our community at all times. About Stupid Cancer: Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Through innovative programming and strategic communications, the organization aims to provide support, resources, education, and a sense of community both online and in-person. For more information, please visit stupidcancer.org. Contact Details Alison Silberman +1 212-619-1040 media@stupidcancer.org Company Website https://stupidcancer.org/

August 03, 2023 09:51 AM Eastern Daylight Time

Image
Article thumbnail News Release

xUTILITY to Lead the Way Integrating Research and Patient Care

xCures

xCures, a trailblazer in healthcare technology, is delighted to unveil xUTILITY, a solution poised to transform the patient registry paradigm in the United States. xUTILITY establishes an instantaneous patient registry platform by retrieving records nationwide and automatically digitizing and structuring the electronic health data into a common data model with AI-enhanced abstraction and source verification, as needed. In order to provide a 360-degree view of patient health, xUTILITY includes comprehensive capture capabilities for Electronic Health Records (EHR) and Social Determinants of Health (SDOH) data. "The integration of research and care is the future of healthcare," said Mika Newton, CEO of xCures. "xUTILITY brings this future to the present by delivering rich, comprehensive, and timely patient data. This connectivity will spur personalized, efficient care and groundbreaking medical discoveries." The platform's ability to capture Real-Time, Regulatory-Grade Clinical Data (RRC) is pivotal to delivering quality patient care and pursuing groundbreaking medical research. xUTILITY's distinctive feature is its ability to accommodate user document uploads, integrated with automated data extraction. The resulting synchronized data architecture introduces a new era of research-driven patient care. Its innovative data extraction process, bolstered by a complete data annotation workflow, adheres to 21 CFR Part 11, signifying xCures' unyielding commitment to data integrity. The unprecedented level of automation offered by xUTILITY translates to a remarkable workforce multiplier, with up to a 30-fold improvement in efficiency of data curation. This efficiency enables healthcare organizations to expedite decision-making, improve health outcomes, and enhance operational effectiveness. With xUTILITY, xCures is charting a course toward a future where the integration of research and care forms the backbone of healthcare delivery. About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. Contact Details xCures Inc Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

August 03, 2023 09:06 AM Eastern Daylight Time

Video
Article thumbnail News Release

Innovative Eyewear CEO says company is leading innovation in smart eyewear; unveils new Blueshift Lens

Innovative Eyewear

Innovative Eyewear Inc CEO Harrison Gross joined Proactive's Stephen Gunnion with insights on the company's mission to revolutionize eyewear with smart technology - and news of the launch of the Lucyd Blueshift Lens. Harrison explained that the core product is a pair of smart glasses that seamlessly blend technology with style, enabling users to stay connected while protecting and correcting their vision. These smart glasses function as headphones, offer noise-canceling microphones, and integrate voice assistants like Siri and Google Voice for hands-free convenience. The addition of the Blueshift Lens provides protection against harmful blue light from digital screens. Gross said the recent introduction of ChatGPT integration brings powerful artificial intelligence (AI) capabilities to the glasses, allowing users to access vast amounts of information effortlessly. He also discussed the company's partnership with renowned fashion brands including Nautica, Eddie Bauer and Reebok, highlighting the vision to make smart eyewear a fashionable and accessible accessory. Although still a niche market, the company is optimistic about the smart eyewear market's growth potential. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 02, 2023 02:26 PM Eastern Daylight Time

Video
Article thumbnail News Release

Capturing Steady Consumer Spending on Health Care with XLV

Select Sector SPDR

One pocket of sector investing that can be easily overlooked is the health care sector, which is typically at the top or near the top of consumer spending and increases year over year. This was amplified during the pandemic. But even post-pandemic, health care continues to be a driver of the U.S. economy and deserves a presence in a diversified portfolio, especially when considering our aging population and shifting demographics. Representing a large portion of the U.S. economy, the health care industry provides essential care, prescriptions, and services that many lives depend on. Given the increasing demand driven by an aging population, investing in this sector can offer substantial opportunities. The Health Care Select Sector SPDR Fund (XLV) offers access to this valuable part of the economy that touches all. XLV tracks health care stocks from within the S&P 500 Index, weighted by market cap. The ETF offers broad exposure to core companies in the U.S. health care industry. The fund’s top 10 holdings* represent over 50% of the fund. UnitedHealth Group is the largest holding at 9.38%, followed by Johnson & Johnson (8.66%), Eli Lilly (7.12%), Merck (5.38%), AbbVie (5.25%), Thermo Fisher Scientific (4.21%), Pfizer (4.05%), Abbott Labs (3.85%), Danaher (3.37%), and Bristol-Myers Squibb (2.60%). Oldest Health Care ETF on Market Launched in 1998, XLV is the oldest health care ETF in the segment and continues to be a go-to tool for advisors and investors. The ETF is used widely for strategic or tactical positions, depending on the portfolio and investor. With more than $40 billion in assets under management and a low expense ratio of 0.10%**, XLV is actively traded with millions of shares exchanged daily. Since XLV is cap-weighted and selects only from the S&P 500, it tilts heavily toward more stable mega-caps. This open-ended fund tracks the Health Care Select Sector Index. But what XLV really does is offer easy access to the top names in the industry, including pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. And packaged in the exchange-traded fund wrapper, XLV offers a diversified approach to investing in the health care sector. For exposure to the U.S. health care market and the consumer spending behind it, XLV opens the door for advisors and investors of all sizes. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. * Holdings, Weightings & Assets as of 7/31/23 subject to change ** Ordinary brokerage fees apply DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL006762 EXP 10/31/23 Contact Details Dan Dolan dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

August 02, 2023 01:57 PM Eastern Daylight Time

Article thumbnail News Release

UNOS Plan Reimagines Governance of US Transplant System to Best Serve Patients

United Network for Organ Sharing

United Network for Organ Sharing (UNOS) officially submitted a plan to the Health Resources and Services Administration (HRSA) that would establish a new governance structure for the OPTN in order to strengthen public trust and oversight and accountability. UNOS is the mission-driven, non-profit organization that serves as the nation’s organ donation and transplant system—the Organ Procurement and Transplantation Network (OPTN)— under contract with and overseen by HRSA. The OPTN Independence Plan, which HRSA requested through a contract modification in May 2023, outlines how best to establish an OPTN Board that is legally independent from the OPTN contractor’s board, with no overlap in membership and with distinct obligations. Creating an independent OPTN Board would require the incorporation of the OPTN as an independent, nonprofit organization. The plan represents the culmination of a multi-year effort. UNOS first requested HRSA engagement in May 2021 to create an independent OPTN Board. In January 2023, UNOS sent a follow-up letter to HRSA Administrator Carole Johnson, advocating for a contract modification that would allow UNOS to submit a roadmap detailing concrete steps to advance board independence. “The roadmap that we submitted is a critical step forward for the nation’s organ donation and transplant system and the patients and families who depend on it,” said UNOS CEO Maureen McBride, Ph.D. “Transplant patients will be best served if the OPTN and its Board are given greater independence. Our plan increases accountability, transparency and good governance, which will lead to greater public trust in the national system.” Since the formation of the OPTN, the OPTN and UNOS have used a unitary board approach, where the UNOS Board also serves as the OPTN Board. This has been done in compliance with the National Organ Transplant Act (NOTA), the OPTN Final Rule and the current OPTN contract held by UNOS. Efforts to reform and improve the national system, however, require a collaborative reimagining of this structure. UNOS’ plan will accomplish several critical goals of UNOS, HRSA, Congress and federal partners. It will provide the continuity of services on which patients rely while ensuring the OPTN’s independence from any current or future OPTN contractors. “The OPTN Independence Plan also promotes competition for the upcoming OPTN contract, eliminating any potential or perceived conflict of interest,” UNOS Board President Dianne LaPointe Rudow, APN-BC, DNP, FAAN said. Creating a legally independent OPTN corporation is a key pillar of UNOS’ Action Agenda and was endorsed by the Senate Finance Committee in its August 2022 report. The proposed plan is subject to HRSA approval. “We are committed to working with HRSA to ensure the successful and timely implementation of any OPTN governance restructuring plan by March 31, 2024,” McBride continued. “It is imperative that we pursue reforms as a unified community, and I am proud of the cooperation at all levels that has resulted in this plan.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

August 02, 2023 01:50 PM Eastern Daylight Time

1 ... 102103104105106 ... 304